

September 26, 2025

To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001

To,  
The Manager – Listing,  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

**Sub.: Outcome of the Board Meeting held on 26th September, 2025**

Pursuant to Regulations 30 and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. Friday, 26th September, 2025, have approved the following agendas:

**1. Approval of Interim Dividend:**

The Board of Directors of the Company, has considered and approved the Interim Dividend of ₹ 2.50 per equity shares on face value of ₹ 1/- per equity shares for the Financial Year 2025-26 amounting to ₹ 705.50 millions. As intimated earlier on 22nd September 2025, the record date for the purpose of payment of dividend shall be **Friday, 3rd October, 2025**, and the interim dividend will be paid within 30 days from the date of the declaration.

**2. Reconstitution of Board Committees:**

The Board has approved reconstitution of following committees of the Board:

Sr. No.	Committees of the Board	Composition of the Committees with effect from 1st October, 2025
1.	<b>Stakeholders Relationship Committee</b>	Ms. Sona Saira Ramasastry - Chairman Mrs. Cherylann Pinto - Member Ms. Patricia Andrews - Member
2.	<b>Risk Management Committee</b>	Mr. Dipankar Bhattacharjee – Chairman Mr. Glenn Saldanha – Member Ms. Patricia Andrews – Member Mr. Anurag Mantri – Member
3.	<b>ESG (Environmental, Social and Governance) Committee</b>	Mr. Glenn Saldanha – Chairman Ms. Sona Saira Ramasastry – Member Mr. Pradeep Kumar Sinha – Member Ms. Patricia Andrews – Member

**Glenmark Pharmaceuticals Limited**

Glenmark House, B. D. Sawant Marg, Andheri (East), Mumbai 400 099, India

T: +91 22 4018 9999 F: +91 22 4018 9986 CIN No. L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)



The meeting of the Board of Directors of the Company commenced at 10:00 a.m. IST and concluded at 10:21 a.m. IST.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Glenmark Pharmaceuticals Limited**



**Harish Kuber**  
**Company Secretary & Compliance Officer**